02:42:35

Virtual Regional Community Workshop (RCW) - Mid Atlantic

05:10

Myeloma Made Simple: Xpovio (Selinexor) Side Effect Management Made Simple | Managing Side Effects

05:08

Myeloma Made Simple: Xpovio (Selinexor) Made Simple | Selinexor for Multiple Myeloma Treatment

03:51

What is the role of ASCT in the frontline setting for African-American patients?

00:58

Don't Wait. Join a Myeloma Support Group Now | support.myeloma.org

02:57

What should be done if a patient relapses while in a clinical trial?

03:01

Navigating Multiple Myeloma Treatment: Insights from Jerry and Jill | CAR T-cell Therapy and More

02:35

Do patients with MGUS always need to undergo a bone marrow test?

03:05

What are CRAB and pre-CRAB criteria in myeloma diagnosis, & how do they affect treatment decisions?

03:26

How valuable is minimal residual disease testing for myeloma patients?

43:20

#MyelomaActionMonth | Q&A with Dr. Urvi A. Shah, Memorial Sloan Kettering: Watch the Replay

04:14

What concerns about the early use of CAR T therapy were addressed in the ODAC hearing?

03:21

TAKE ACTION #myelomaactionmonth | Raise Myeloma Awareness

01:01:55

Living Well With Myeloma: Understanding Medicare Changes in 2024 and Beyond

03:27

Jerry Schock's Multiple Myeloma Journey: A Patient's Experience from Diagnosis to Treatment Options

01:31

#MyelomaActionMonth | What people living with myeloma blood cancer wish you knew about the disease.

05:23

What are considerations for myeloma patients with immune therapy targets, side effects & monitoring?

01:02

International Myeloma Foundation M-Power | To Change the Course of Myeloma in the Black Community

06:05

Empowering Insights on Myeloma: Surviving & Thriving | Oya and Carri

32:45

#MyelomaActionMonth | Q&A with IMF NLB Member Beth Faiman: Watch the Replay

28:35

#MyelomaActionMonth | Q&A with Dr. Mikhael and Kaur at the Patient Family Seminar: Watch the Replay

02:56

What are early insights from iStopMM regarding preventing myeloma progression?

11:50

2023 M-Power Detroit | Black Cancer Patients and Communication in Care, What the Research Tells Us

18:58

2023 M-Power Detroit | The Importance of Communication In Your Care

17:03

2023 M-Power Detroit | Interview with Dr. Craig Cole

26:52

2023 M-Power Detroit | Telling Our Stories — Patient Panel

33:14

2023 M-Power Detroit | How We Treat Myeloma

17:15

2023 M-Power Detroit | Race Matters in Myeloma Care and Survival

16:20

2023 M-Power Detroit | Myeloma Made Simple

00:49

Ice-T Talks Health Equity: Real Facts About Multiple Myeloma in the Black Community

02:53

#MyelomaActionMonth 2024 | Myeloma Patients and Care Partners From Around the World Raise Awareness

20:19

2023 M-Power Detroit | Welcome and Introductions

01:44

Nick Lenoir, 6-Year Survivor | Insights, Strength, and Connection during Myeloma ACTION Month

04:11

What is the significance of mass spectrometry in measuring myeloma protein levels?

02:40

Is using a four-drug combination as the firstline therapy for myeloma feasible?

01:45

Embracing Purpose: Diane Hunter's Journey with Myeloma | Overcoming Challenges, Finding Hope

03:27

Cancer, Laughter, and Coping: Oya Gilbert's Journey with Multiple Myeloma | Living Well with Myeloma

00:06

Take Action During Myeloma Action Month

07:36

ASH23: Real World Outcomes with Ide-Cel CAR-T Cell Therapy for Relapsed Myeloma | Surbhi Sidana, MD

03:10

Is the face of myeloma changing?

03:44

Navigating Healthcare: Advocacy and Empathy in Fighting Multiple Myeloma

06:38

Oya Gilbert's Journey with Multiple Myeloma: Challenges & Advocacy | Delayed Diagnosis Part 3

06:59

ASH23: P-BCMA-ALLO1 CAR-T Therapy for Relapsed Myeloma Patients | Bhagirathbhai Dholaria, MBBS

11:42

ASH23: Mezigdomide (MEZI) Combo Therapy for Relapsed/Refractory Myeloma | Paul Richardson, MD

07:45

ASH23: RVd Alone vs Rvd + ASCT in Newly Diagnosed African American MM Patients | Paul Richardson, MD

01:28

Black History Month: Diane Hunter's Journey of Support and Resilience | Embracing a Strong Network

06:18

ASH23: Isatuximab Combo in Iskia Trial for Pre- & Post-Transplant Treatment | Francesca Gay, MD, PhD

00:38

M-POWER: Ice-T Sets the Record Straight On Multiple Myeloma, It's Not Melanoma | Black History Month

02:47

Living with Myeloma: Oya's Diagnostic Journey | Patient Story: Diagnosis Part 2: Delayed Diagnosis

00:51

M-POWER | Actor and Artist Ice-T Raises Awareness of Myeloma in the Black Community

02:28

Black History Month: Diane Hunter's Empowering Advice on Self-Awareness and Health Advocacy

10:43

ASH23: Elranatamab Effective in Relapsed Myeloma Post-BCMA CAR-T | Daniel Sherbenou, MD, PhD

09:52

ASH23: Post ASH Summary | Joseph Mikhael, MD

05:10

2023 Innovation and Impact Report | International Myeloma Foundation Reports on Key Wins in Myeloma

06:51

ASH23: SeaLAND Study — Selinexor and Lenalidomide Combo for Newly Diagnosed Myeloma | Dr. Hang Quach

09:22

ASH23: Response to Linvoseltamab in Relapsed Myeloma Patients – Linker-MM1 Study | Hans Lee, MD

07:26

ASH23: Sonrotoclax in Combo with Dexamethasone for Relapsed Myeloma with t(11;14) | Dr. Hang Quach

06:40

ASH23: Frontline Treatment DRd vs. VRd for Transplant-Ineligible Myeloma Patients | Doris Hansen, MD

09:58

ASH23: KarMMa-3 Study: Ide-Cel for Triple-Class-Exposed RRMM Patients | Paula Rodriguez Otero, MD

07:44

ASH23: Abbv-383 BCMA x CD3 Bispecific Antibody for Relapsed/Refractory Myeloma | Ravi Vij, MD, MBA